Sequential cfDNA samples obtained during the clinical disease course were measured by ddPCR for the patient-specific breakpoint and by the RASSF1A-M assay (Figure 4 for patients with neuroblastoma, Figure 5 for patients with rhabdomyosarcoma and Ewing sarcoma). This evidence concerns the gene RASSF1 and neuroblastoma.